Amarantus Bioscience Holdings
(OTC: AMBS)

Amarantus BioScience Holdings, Inc. (OTC: AMBS) is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

The Company’s lead therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia, one of the most difficult problems facing patients with Parkinson’s disease. Eltoprazine is currently in a Phase 2b clinical trial with results from the study expected in 2016. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.

The company’s diagnostics division, Amarantus Diagnostics is dedicated to the development and commercialization of neurology diagnostic products. The company’s lead diagnostic product, LymPro Test® is a blood based assay to diagnose Alzheimer’s disease and is approved for investigational use only to be used in biotech and pharmaceutical clinical trials.

Amarantus Diagnostics is also developing MSPrecise®, a proprietary, next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.

Find a broker to begin trading AMBS now

Company Name Amarantus Bioscience Holdings
Market/Symbol OTC: AMBS
Recent Price
Market Cap $3.79M
Avg. Daily Vol. (3m) 189,066
Price/Book N/A
Price/Cash Flow N/A
As of Dec. 12, 2017
*Source: QuoteMedia


Begin trading AMBS

 Find Broker

SIGN UP FOR EMAIL ALERTS

BE THE FIRST TO RECEIVE BREAKING NEWS

Recent Company Videos


Amarantus Bioscience Holdings Presentation at RedChip's December 2017 Conference

Dec. 11, 2017

Visit https://www.redchip.com/events/14 to view the PowerPoint presentation. Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.…


Amarantus Bioscience Holdings Latest News


Apr. 21, 2016 | 4:04 pm

Latest Investor Presentation

Latest Investor Presentation

 View Full Presentation |  Download

Ask the CEO



Receive AMBS Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market